Our 3D tumor‐on‐a‐chip results were consistent with the results from studies testing PARP1 inhibitors in combination with chemotherapy in breast cancer trials,11 and consistent with results from another in vitro study targeting ovarian cancer.35 Many TNBC studies have shown that the combinations do not provide benefit beyond the standard of care. This evidence concerns the gene PARP1 and breast cancer.